<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809484</url>
  </required_header>
  <id_info>
    <org_study_id>D5392L0027</org_study_id>
    <nct_id>NCT00809484</nct_id>
  </id_info>
  <brief_title>Arimidex Bone Mass Index and Oral Bisphosphonates</brief_title>
  <acronym>ARBI</acronym>
  <official_title>A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Breast Surgeons Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Breast Surgeons Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the management of bone health in postmenopausal women with early breast cancer
      (BCA) scheduled to receive anastrozole. Postmenopausal women with hormone receptor-positive
      early BCA are assigned to 1 of 3 strata depending on their pre-existing risk of fragility
      fracture. Patients (pts) with a bone mineral density (BMD) T-score &lt;-2.0 for either spine or
      hip are designated higher-risk (H) for fracture and receive anastrozole 1 mg/day plus
      risedronate orally. Moderate-risk (M) pts (T-score &lt;-1.0 for spine or hip but -2.0 at both
      sites) are randomized to receive anastrozole plus risedronate (A+R) or anastrozole alone. Pts
      with T-scores -1.0 at both spine and hip were designated lower-risk (L) and receive
      anastrozole alone. All pts receive calcium and vitamin D. Lumbar spine and total hip BMD are
      assessed at baseline, 12, and 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">220</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Bone Density</condition>
  <arm_group>
    <arm_group_label>1: Low risk</arm_group_label>
    <description>Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:Moderate risk</arm_group_label>
    <description>Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, +/- Risedronate 35mg orally once a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3:High risk</arm_group_label>
    <description>Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, Risedronate 35mg orally once a week</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Posmenopusal women with endocrine responsive breast cancer who are treated with the
        aromatase inhibitor anastrozole
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  ER and or PgR positive breast cancer

          -  Completed Surgery and =/- chemotherapy

        Exclusion Criteria:

          -  metastases

          -  history of fractures

          -  HRT or SERMs

          -  Liver or kidney disfunction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hellenic Breast Surgeons Society</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>January 3, 2009</last_update_submitted>
  <last_update_submitted_qc>January 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Markopoulos Christos</name_title>
    <organization>Hellenic Breast Surgeons Society</organization>
  </responsible_party>
  <keyword>Arimidex</keyword>
  <keyword>Bone Mineral density</keyword>
  <keyword>Bisphosphonates</keyword>
  <keyword>Aromatase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

